Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myelo001 for Chemotherapy-Induced Neutropenia in Breast Cancer
NCT02692742Phase 2Completed
- Sponsor
- Myelo Therapeutics
- Start
- Mar 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chemotherapy-induced neutropenia (CIN) comparing Myelo001 with Placebo (2 arms). Primary endpoints: Threshold area over the curve (AOC1) of ANC at 22 days, Threshold area over the curve (AOC3) of ANC at 22 days and 1 more. Started Mar 2016; status: completed.
02
Drugs
Ingavirin
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT02692742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02692742.